Register Login

PMV PHARMACEUTICALS, INC. (PMVP)

SymbolPMVP
NamePMV PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address400 ALEXANDER PARK DRIVE,SUITE 301, PRINCETON, New Jersey, 08540, United States
Telephone+1 609 642-6670
Fax—
Email—
Websitehttps://www.pmvpharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001699382
Description

PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

Additional info from NASDAQ:
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which has the ability to eliminate cancer cells.

2026-07-10 12:41

New Form SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. <b>Filed:</b> 2026-07-10 <b>AccNo:</b> 0001172661-26-002568 <b>Size:</b> 7 KB

Read more
2026-06-05 20:32

Stelzer Laurie 🟢 acquired 42.0K shares (1 derivative) of PMV Pharmaceuticals, Inc. (PMVP) at $1.19 Transaction Date: Jun 04, 2026 | Filing ID: 000003

Read more
2026-06-05 20:30

LEVINE ARNOLD J 🟢 acquired 42.0K shares (1 derivative) of PMV Pharmaceuticals, Inc. (PMVP) at $1.19 Transaction Date: Jun 04, 2026 | Filing ID: 000002

Read more
2026-06-05 20:25

Gallagher Carol Giltner 🟡 adjusted position in 42.0K shares (3 derivative) of PMV Pharmaceuticals, Inc. (PMVP) at $1.19 Transaction Date: Jun 04, 2026 | Filing ID: 000002

Read more
2026-06-05 20:23

FLOWERS KIRSTEN 🟢 acquired 42.0K shares (1 derivative) of PMV Pharmaceuticals, Inc. (PMVP) at $1.19 Transaction Date: Jun 04, 2026 | Filing ID: 000002

Read more
2026-06-05 20:20

BAUM CHARLES M 🟢 acquired 42.0K shares (1 derivative) of PMV Pharmaceuticals, Inc. (PMVP) at $1.19 Transaction Date: Jun 04, 2026 | Filing ID: 000003

Read more
2026-06-05 12:10

(99% Neutral) PMV PHARMACEUTICALS, INC. (PMVP) Announces Regulatory Update

Read more
2026-05-15 17:07

New Form SCHEDULE 13G/A - PMV Pharmaceuticals, Inc. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001012975-26-000440 <b>Size:</b> 16 KB

Read more
2026-05-12 12:00

(30% Negative) PMV PHARMACEUTICALS, INC. (PMVP) Reports Q2 2026 Financial Results

Read more
2026-04-22 12:00

PMV Pharmaceuticals Announces Board Chair Transition

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT07372625 A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharm… Phase1 TP53 Y220C Mutation Recruiting 2026-02-04 2028-01-01 ClinicalTrials.gov
NCT06616636 A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With… Phase1 Myelodysplastic Syndrome Recruiting 2025-01-30 2029-08-27 ClinicalTrials.gov
NCT06362642 A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of P… Phase1 Healthy Volunteers Completed 2024-03-28 2024-10-22 ClinicalTrials.gov
NCT06054464 A Study to Investigate the Effects of Acid Reducing Agents on Pharmacokinetics … Phase1 Healthy Volunteers Completed 2023-09-19 2024-02-06 ClinicalTrials.gov
NCT05523687 AME Study of [14C]-PC14586 in Healthy Male Participants Phase1 Healthy Male Volunteers Completed 2022-09-06 2022-11-30 ClinicalTrials.gov
NCT05249348 Effect of Food on PC14586 in Healthy Volunteers and the PK of PC14586 in Health… Phase1 Healthy Volunteers Completed 2021-12-20 2022-06-09 ClinicalTrials.gov
NCT04585750 The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP… Phase1 Advanced Solid Tumor Recruiting 2020-10-29 2027-12-31 ClinicalTrials.gov
Total clinical trials: 7
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
pembrolizumab Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT04585750
rezatapopt Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT04585750
[14C]-PC14586 Other Phase PHASE1 Healthy Male Volunteers COMPLETED NCT05523687
Itraconazole Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06362642
PC14586 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06362642
Famotidine Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06054464
Rabeprazole Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06054464
PC14586 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT06054464
PC14586 Other Phase PHASE1 Healthy Volunteers COMPLETED NCT05249348
Rezatapopt Other Phase PHASE1 Myelodysplastic Syndrome RECRUITING NCT06616636
Azacitidine Other Phase PHASE1 Myelodysplastic Syndrome RECRUITING NCT06616636
rezatapopt Other Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
midazolam hydrochloride syrup Other Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
repaglinide 0.5 mg tablet Other Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
rosuvastatin 10 mg tablet Other Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
metformin hydrochloride 500 mg tablet Other Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
pembrolizumab Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT04585750
rezatapopt Other Phase PHASE1 Advanced Solid Tumor RECRUITING NCT04585750
midazolam hydrochloride syrup DRUG Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
repaglinide 0.5 mg tablet DRUG Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
rosuvastatin 10 mg tablet DRUG Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
metformin hydrochloride 500 mg tablet DRUG Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
Rezatapopt DRUG Phase PHASE1 Myelodysplastic Syndrome RECRUITING NCT06616636
Azacitidine DRUG Phase PHASE1 Myelodysplastic Syndrome RECRUITING NCT06616636
Itraconazole DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06362642
Famotidine DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06054464
Rabeprazole DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06054464
[14C]-PC14586 DRUG Phase PHASE1 Healthy Male Volunteers COMPLETED NCT05523687
PC14586 DRUG Phase PHASE1 Healthy Volunteers COMPLETED NCT06362642
pembrolizumab DRUG Phase PHASE1 Advanced Solid Tumor RECRUITING NCT04585750
rezatapopt DRUG Phase PHASE1 TP53 Y220C Mutation RECRUITING NCT07372625
Total products: 31